Clinical trials: Zoledronic Acid
Multiple Myeloma, Breast Cancer
Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
The investigators major aim is to determine whether there is a difference in the retention of zoledronic acid in multiple myeloma patients, compared to patients with breast cancer metastasis to bone.
- Trial name
- NCT00760370
- Testing
- Zoledronic Acid
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Vejle Hospital
Male Osteoporosis
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
- Trial name
- NCT00439647
- Testing
- Zoledronic acid 5 mg iv
- Where
- 128 sites in Argentina, Australia and 21 more
- Volunteers
- 1,199 people
- Sponsor
- Novartis Pharmaceuticals
Bone Neoplasms
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events…
- Trial name
- NCT00434447
- Testing
- Zoledronic acid
- Where
- 10 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
This extension study is designed to assess the long term safety and efficacy of zoledronic acid in postmenopausal women with osteoporosis who have participated in the CZOL446H2301 (NCT00049829): HORIZON Pivotal Fracture Trial.
- Trial name
- NCT00145327
- Testing
- Zoledronic Acid
- Where
- 31 sites in United States, Germany
- Volunteers
- 2,456 people
- Sponsor
- Novartis
Osteoporosis, Osteopenia
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
The purpose of this study is to apply a novel advanced magnetic resonance imaging methodology to evaluate the response to drug intervention involving two treatment arms of postmenopausal participants with osteoporosis, randomized…
- Trial name
- TERIZOL (NCT01153425)
- Testing
- Virtual Bone Biopsy, Teriparatide, Zoledronic Acid
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pennsylvania
Hematopoietic Stem Cell Transplantation
Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors
The purpose of this pilot study is to investigate the safety and preliminarily assess efficacy of early intervention with zoledronate in high risk pediatric hematopoietic stem cell transplantation (HSCT) patients to prevent the…
- Trial name
- NCT07375290
- Testing
- Zoledronate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Breast Cancer With Bone Metastasis
Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions
Zoledronic acid selectively binds to bone and protects it from being metastasized by tumor cells. This study evaluates the safety and efficacy of zoledronic acid when added to standard therapies in breast cancer patients with…
- Trial name
- NCT00372710
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Novartis
Prostate Cancer, Adenocarcinoma of the Prostate
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread…
- Trial name
- NCT00181558
- Testing
- Atrasentan, Zoledronic Acid (Zometa)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Massachusetts General Hospital
Osteoarthritis, Hip
The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip
Hip Osteoarthritis (OA) is one of the most common diseases affecting the ageing population. No specific and safe treatment slowing the development of hip OA as reflected in reduced joint space narrowing has been developed so far.
- Trial name
- NCT04303026
- Testing
- Zoledronic Acid, Saline 0.9%
- Where
- Norway
- Volunteers
- 70 people
- Sponsor
- Vestre Viken Hospital Trust
Osteopenia
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
- Trial name
- NCT00132808
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 581 people
- Sponsor
- Novartis Pharmaceuticals
Triple Negative Breast Cancer
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer
Recent evidences suggest that zoledronate, one of the most used bisphosphonates (BPs) in the clinical setting for the prevention and treatment of bone metastasis in cancer patients, may have antitumor activity in early breast…
- Trial name
- YAPPETIZER (NCT03358017)
- Testing
- Zoledronate, Atorvastatin 80mg, Standard neoadjuvant cht
- Where
- 9 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Prostatic Neoplasms, Bone Density
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.
- Trial name
- NCT00489905
- Testing
- Zolderonic acid (Zometa)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hospital Authority, Hong Kong
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer Metastatic
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
Exploring the efficacy and safety of zoledronic acid combined with neoadjuvant chemotherapy (EC-T) in neoadjuvant treatment for early-stage or locally advanced triple-negative breast cancer, the trial protocol of zoledronic acid…
- Trial name
- NCT06876636
- Testing
- Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Xijing Hospital
Osteoporosis, Postmenopausal
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
This was a prospective, randomized, open-label, two arm phase III trial designed to evaluate the efficacy and safety of zoledronic acid in preventing bone loss in postmenopausal women with operable breast cancer who had received…
- Trial name
- NCT00332709
- Testing
- Letrozole, Zoledronic acid
- Where
- 23 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Novartis
Hepatocellular Carcinoma
Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Sorafenib ,an oral multikinase inhibitor targeting several tyrosine-kinase receptors with antiangiogenesis and antiproliferation of HCC, is the first approved target therapy for HCC.
- Trial name
- NCT01259193
- Testing
- Sorafenib and Zoledronic Acid
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Complex Regional Pain Syndromes
The Use of Zoledronic Acid to Complex Regional Pain Syndrome
To evaluate the efficacy and the safety of using a single, intravenous 5mg dose of zoledronic acid in managing pain in Complex Regional Pain Syndrome patients.
- Trial name
- Aclasta (NCT01788176)
- Testing
- Zoledronic acid
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo General Hospital
Primary Breast Cancer
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases.
- Trial name
- MRD-1 (NCT00172068)
- Testing
- Zoledronic acid + Calcium/Vitamin D
- Where
- 4 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Osteoporosis
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women…
- Trial name
- NCT00436917
- Testing
- zoledronic acid, Letrozole as adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Breast Neoplasms, Bone Loss
Bone Loss Treatment From Adjuvant Zoledronate Efficacy
The main purpose of this study is to observe and assess the impact of adjuvant zoledronate on bone density in breast cancer patients.
- Trial name
- BLAZE (NCT01623908)
- Testing
- Zoledronate
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University